PRODUCT TYPES – Page 15

Assay drift in oncology manufacturing: FDA/EMA investigation expectations

Detection of assay drift typically arises during routine operations through various signals that indicate a potential quality issue. Common symptoms include:Click to read the full article.

Finished product CCIT failure during CPV annual product review: stability strategy adjustments and packaging risk mitigation steps

Detecting CCIT failures involves observing specific symptoms that may manifest during routine inspections or product tests. Common signals that indicate potential issues include:Click to read the full article.

Cross-contamination risk after equipment cleaning: FDA/EMA investigation expectations

Identifying the early signals of cross-contamination is crucial for timely intervention. Common symptoms might include:Click to read the full article.

Finished product microbial limits failure during recall risk assessment: FDA-compliant investigation flow and batch disposition decision tree

When a finished product microbial limits failure occurs, several signals may indicate potential issues:Click to read the full article.

Potency OOS after equipment cleaning: FDA/EMA investigation expectations

When dealing with a potency OOS following equipment cleaning, clear signals can help identify the immediate need for an investigation. Common symptoms include:Click to read the full article.

Finished product CCIT failure after equipment calibration drift found: CAPA plan that inspectors accept (with effectiveness checks and due dates)

The first step in understanding CCIT failures is identifying the symptoms or signals that indicate a potential issue. Common signs that may suggest a failure in CCIT due to equipment…

Stability failure during shared facility campaign: risk assessment for patient safety

Identifying symptoms and signals early in the manufacturing process is critical to mitigating stability failures. Common indicators on the production floor or in the laboratory may include:Click to read the…

Finished product nitrosamine risk assessment gap after method transfer to a new QC lab: manufacturing vs lab root cause mapping and required evidence

Identifying symptoms or signals during the manufacturing or evaluation phases is essential to trigger an investigation into potential analysis gaps. Some common indicators include:Click to read the full article.

Potency OOS after equipment cleaning: containment CAPA and effectiveness checks

The identification of signals suggesting potential potency OOS following equipment cleaning is crucial. Symptoms might manifest during routine quality control testing or inadvertently during a production run. Common indicators can…

Finished product nitrosamine risk assessment gap during PAI / FDA inspection readiness: risk assessment for patient impact and field alert / recall triggers

The presence of nitrosamines in finished pharmaceutical products can lead to serious regulatory repercussions and potential recalls. Symptoms or signals indicating a gap in nitrosamine risk assessment may include:Click to…

Stability failure during inspection prep: risk assessment for patient safety

Detecting signals of stability failure requires vigilance across manufacturing, quality control, and storage environments. Common symptoms may include:Click to read the full article.

Finished product packaging leakage complaint after packaging material change: manufacturing vs lab root cause mapping and required evidence

The investigation begins with identifying the symptoms or signals that prompted the complaint regarding packaging leakage. Key indicators could include:Click to read the full article.